Form 4: Cingulate Inc. Executive Matthew Brams Acquires Stock Options as Part of 2024 Bonus

Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, was granted stock options as part of his 2024 bonus.

Summary

• Matthew Brams, the EVP and Chief Medical Officer of Cingulate Inc., acquired 2,748 stock options on January 17, 2025.
• These options were granted as part of his 2024 bonus.
• The options have an exercise price of $4.76 per share.
• The options are exercisable starting January 17, 2025, and expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to a key executive like Matthew Brams can be seen as a positive incentive and alignment of interests with shareholders.
• The options have a 10 year term, which is a long term incentive.

Management Comments

• The option was granted for a portion of Mr. Bram's 2024 bonus.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting and expiration terms of these options are typical for executive compensation packages.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company's success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cingulate Inc., Matthew Brams, bonus, equity